TG Therapeutics Inc (NASDAQ:TGTX) shares, rose in value on Thursday, March 27, with the stock price down by -1.45% to the previous day’s close as strong demand from buyers drove the stock to $40.20.
Actively observing the price movement in the last trading, the stock closed the session at $40.79, falling within a range of $39.8 and $41.0471. The value of beta (5-year monthly) was 2.301 whereas the PE ratio was 287.97 over 12-month period. Referring to stock’s 52-week performance, its high was $43.32, and the low was $12.93. On the whole, TGTX has fluctuated by 37.01% over the past month.
With the market capitalization of TG Therapeutics Inc currently standing at about $6.31 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-02.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 553.48M, with a low estimate of 114.6M and a high estimate of 119.9M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 117.07M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TGTX’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 1.84, with the price of TGTX currently trading nearly 3.68% and 17.72% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 58.68, while the 7-day volatility ratio is showing 3.83% which for the 30-day chart, stands at 6.76%. Furthermore, TG Therapeutics Inc (TGTX)’s beta value is 2.18, and its average true range (ATR) is 2.05.
A comparison of TG Therapeutics Inc (TGTX) with its peers suggests the former has fared considerably weaker in the market. TGTX showed an intraday change of -1.45% in last session, and over the past year, it grew by 156.21%%.
Data on historical trading for TG Therapeutics Inc (NASDAQ:TGTX) indicates that the trading volumes over the past 10 days have averaged 2.55 and over the past 3 months, they’ve averaged 2.63 million. According to company’s latest data on outstanding shares, there are 155.84 million shares outstanding.
Nearly 9.96% of TG Therapeutics Inc’s shares belong to company insiders and institutional investors own 62.27% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 26.23 million shares as on 2025-03-14, resulting in a short ratio of 7.84. According to the data, the short interest in TG Therapeutics Inc (TGTX) stood at 1843.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 25.74 million. The stock has risen by 33.55% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TGTX stock heading into the next quarter.
